Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New IVF drug combo shows promise for better embryos

NCT ID NCT05873725

Disease control Sponsor: Clinique Ovo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a high dose of a fertility drug called follitropin delta, mixed with another hormone (hCG), in 118 women undergoing IVF. The goal was to see if this combination could improve the number of good-quality embryos. The study was completed and focused on women aged 18-42 with regular cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

118 people

The number who actually took part.

Started

May 2023

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women consulting the clinic for fertility issues that require in vitro fertilization

Ages

18 to 42 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women 18 to 42 years of age undergoing IVF/ICSI cycle * IVF antagonist protocol * Regular menstrual cycles of 24-35 days * Presence of both ovaries Exclusion Criteria: * Endometriosis stage III/IV * History of recurrent miscarriages, defined as ≥ 3 consecutive losses * Women undergoing ovarian stimulation for oncologic or elective fertility preservation * Women participating in any other research project * Hypersensitivity to follitropin delta and/or human chorionic gonadotropin * Use of Growth Hormone (GH) during the stimulation cycle

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder ventricular fibrillation, paroxysmal familial, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility IVF

Contacts and locations

Locations

  • Clinique Ovo

    Montreal, Quebec, H4P 2S4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.